Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00975767 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT00975767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00975767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2009
Completion date
August 31, 2014
Enrollment
126 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, non-small cell lung cancer